Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2020

View Archived Issues

First-in-human study tests BI-764524 in diabetic macular ischemia

Akeso begins first-in-human study of AK-120 for atopic dermatitis

JS InnoPharm evaluates JSI-1187 for advanced solid tumors with MAPK pathway mutations

Placental attachment theory

CH-7233163: an EGFR inhibitor active against osimertinib-resistant EGFR-T790M/C797S mutations

Novel CTH-004 CAR T cells for the treatment of ovarian cancer

Machine learning, GWAS divide and conquer PCOS

TN1-006: a gene therapy-mediated cardiac reprogramming candidate with potential for MI treatment

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

CECSi cells show promising preclinical results for the treatment of bullous keratopathy

New gamma-secretase inhibitors identified at Roche

Lynk Pharmaceuticals patents Janus kinase inhibitors

Dual CACNA2D1/mu-opioid receptor ligands discovered at Esteve

Emerald Health Biotechnology Espana identifies monoglyceride lipase inhibitors

FDA approves IND for phase II study of antroquinonol in patients with COVID-19

Phase I study of DS-1062 expanded to include patients with TNBC

Menarini plans phase Ib/II study of MEN-1611 in metastatic colorectal cancer

FDA clears initiation of phase III trial of siltuximab for COVID-19-associated ARDS

Early positive data for BNT-162b1 vaccine candidate against SARS-CoV-2

Recruitment starts in phase II study of DUR-928 in COVID-19 with acute liver or kidney injury

European Commission approves canagliflozin label update

Promising efficacy of SJP-1602 in models of TNBC

RO-7297089 begins first-in-human study for relapsed or refractory multiple myeloma

Chinese phase I study evaluates TQB-3558 for solid tumors

European Commission approves Janssen's Ebola vaccine regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...